Wallis CJD, et al. - In this updated, comprehensive meta-analysis, researchers evaluated if the effectiveness of immunotherapy in advanced cancers differed by patient sex. They conducted a systematic review of studies (n = 23) indexed in MEDLINE (PubMed), Embase, and Scopus from the inception of these databases to October 2, 2018. If overall survival was reported and if data was stratified by patient sex, randomized clinical trials comparing immunotherapy with the standard of care in the treatment of advanced solid-organ malignant neoplasms were included. This meta-analysis involved 9,322 men (67.9%) and 4,399 women (32.1%); the majority of patients were in their 70s. For both men and women, an overall survival benefit of immunotherapy was found. According to stratified analyses and using overall survival as the outcome, no statistically significant correlation between patient sex and efficacy of immunotherapy was found in treating advanced cancers.